{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:34:02Z","timestamp":1781620442695,"version":"3.54.5"},"reference-count":56,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRU339, 428091001, 428094573"],"award-info":[{"award-number":["CRU339, 428091001, 428094573"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Federal Ministry of Health","award":["V-2020.12 \/ 1503_68403 \/ 2021-2022"],"award-info":[{"award-number":["V-2020.12 \/ 1503_68403 \/ 2021-2022"]}]},{"name":"German Federal Ministry of Health","award":["ZMI1-2521KDG103"],"award-info":[{"award-number":["ZMI1-2521KDG103"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>SARS-CoV-2 mRNA vaccination of healthy individuals is highly immunogenic and protective against severe COVID-19. However, there are limited data on how disease-modifying therapies (DMTs) alter SARS-CoV-2 mRNA vaccine immunogenicity in patients with autoimmune diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>As part of a prospective cohort study, we investigated the induction, stability and boosting of vaccine-specific antibodies, B cells and T cells in patients with multiple sclerosis (MS) on different DMTs after homologous primary, secondary and booster SARS-CoV-2 mRNA vaccinations. Of 126 patients with MS analysed, 105 received either anti-CD20-based B cell depletion (aCD20-BCD), fingolimod, interferon-\u03b2, dimethyl fumarate, glatiramer acetate, teriflunomide or natalizumab, and 21 were untreated MS patients for comparison.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In contrast to all other MS patients, and even after booster, most aCD20-BCD- and fingolimod-treated patients showed no to markedly reduced anti-S1 IgG, serum neutralising activity and a lack of receptor binding domain-specific and S2-specific B cells. Patients receiving fingolimod additionally lacked spike-reactive CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cell responses. The duration of fingolimod treatment, rather than peripheral blood B and T cell counts prior to vaccination, determined whether a humoral immune response was elicited.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The lack of immunogenicity under long-term fingolimod treatment demonstrates that functional immune responses require not only immune cells themselves, but also access of these cells to the site of inoculation and their unimpeded movement. The absence of humoral and T cell responses suggests that fingolimod-treated patients with MS are at risk for severe SARS-CoV-2 infections despite booster vaccinations, which is highly relevant for clinical decision-making and adapted protective measures, particularly considering additional recently approved sphingosine-1-phosphate receptor antagonists for MS treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2022-329395","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:20:41Z","timestamp":1657804841000},"page":"960-971","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod"],"prefix":"10.1136","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7909-020X","authenticated-orcid":false,"given":"Lil","family":"Meyer-Arndt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Fauchere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Vanshylla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Loyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Henze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Dingeldey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"J\u00fcrchott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Mangold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardit","family":"Maraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Braginets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chotima","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Nitsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"de la Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Ratswohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Sawitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlo","family":"Holenya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3375-6889","authenticated-orcid":false,"given":"Ulf","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif E","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bellmann-Strobl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5927-7018","authenticated-orcid":false,"given":"Claudia","family":"Giesecke-Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"2023051801202580000_93.9.960.1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002630"},{"key":"2023051801202580000_93.9.960.2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41575-021-00480-y","article-title":"COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology","volume":"18","author":"Neurath","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2023051801202580000_93.9.960.3","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1111\/ene.14690","article-title":"COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response","volume":"28","author":"Zabalza","year":"2021","journal-title":"Eur J Neurol"},{"key":"2023051801202580000_93.9.960.4","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001001"},{"key":"2023051801202580000_93.9.960.5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol"},{"key":"2023051801202580000_93.9.960.6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26028"},{"key":"2023051801202580000_93.9.960.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102180","article-title":"Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod","volume":"42","author":"Foerch","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2023051801202580000_93.9.960.8","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103371","article-title":"COVID-19 outcomes in persons with multiple sclerosis treated with rituximab","volume":"57","author":"Iyer","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2023051801202580000_93.9.960.9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012753"},{"key":"2023051801202580000_93.9.960.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107456"},{"key":"2023051801202580000_93.9.960.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"2023051801202580000_93.9.960.12","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.19.1.80-94.2006"},{"key":"2023051801202580000_93.9.960.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170710"},{"key":"2023051801202580000_93.9.960.14","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ibd\/izx101","article-title":"Immunogenicity of quadrivalent influenza vaccine for patients with inflammatory bowel disease undergoing immunosuppressive therapy","volume":"24","author":"Shirai","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2023051801202580000_93.9.960.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01507-2"},{"key":"2023051801202580000_93.9.960.16","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103682","article-title":"Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: effects of disease modifying therapies","volume":"59","author":"Habek","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2023051801202580000_93.9.960.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103729","article-title":"Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients","volume":"60","author":"Bajwa","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2023051801202580000_93.9.960.18","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26346"},{"key":"2023051801202580000_93.9.960.19","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1177\/13524585221089540","article-title":"Is humoral and cellular response to SARS-CoV-2 vaccine modified by Dmt in patients with multiple sclerosis and other autoimmune diseases?","volume":"28","author":"Zabalza","year":"2022","journal-title":"Mult Scler"},{"key":"2023051801202580000_93.9.960.20","doi-asserted-by":"crossref","DOI":"10.1126\/science.abh1823","article-title":"Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination","volume":"374","author":"Loyal","year":"2021","journal-title":"Science"},{"key":"2023051801202580000_93.9.960.21","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd7728"},{"key":"2023051801202580000_93.9.960.22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","article-title":"SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19","volume":"587","author":"Braun","year":"2020","journal-title":"Nature"},{"key":"2023051801202580000_93.9.960.23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41594-020-0469-6","article-title":"Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2","volume":"27","author":"Huo","year":"2020","journal-title":"Nat Struct Mol Biol"},{"key":"2023051801202580000_93.9.960.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2180-5"},{"key":"2023051801202580000_93.9.960.25","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-020-01472-1"},{"key":"2023051801202580000_93.9.960.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.04.015"},{"key":"2023051801202580000_93.9.960.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20241-w"},{"key":"2023051801202580000_93.9.960.28","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4250"},{"key":"2023051801202580000_93.9.960.29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41590-021-01088-9","article-title":"BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2","volume":"23","author":"Brewer","year":"2022","journal-title":"Nat Immunol"},{"key":"2023051801202580000_93.9.960.30","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe1107"},{"key":"2023051801202580000_93.9.960.31","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"key":"2023051801202580000_93.9.960.32","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-05950-x"},{"key":"2023051801202580000_93.9.960.33","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-013-9465-5"},{"key":"2023051801202580000_93.9.960.34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2018.08.002","article-title":"Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo","volume":"96","author":"Dominguez-Villar","year":"2019","journal-title":"J Autoimmun"},{"key":"2023051801202580000_93.9.960.35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19002-6","article-title":"SLAMF7 and IL-6R define distinct cytotoxic versus helper memory CD8+ T cells","volume":"11","author":"Loyal","year":"2020","journal-title":"Nat Commun"},{"key":"2023051801202580000_93.9.960.36","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.42060","article-title":"B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab","volume":"74","author":"Stefanski","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023051801202580000_93.9.960.37","doi-asserted-by":"crossref","first-page":"103539","DOI":"10.1016\/j.ebiom.2021.103539","article-title":"B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19","volume":"70","author":"Zollner","year":"2021","journal-title":"EBioMedicine"},{"key":"2023051801202580000_93.9.960.38","doi-asserted-by":"crossref","first-page":"eabl5344","DOI":"10.1126\/sciimmunol.abl5344","article-title":"BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype","volume":"6","author":"Guerrera","year":"2021","journal-title":"Sci Immunol"},{"key":"2023051801202580000_93.9.960.39","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1177\/13524585211049391","article-title":"Humoral immune response after COVID-19 in multiple sclerosis: a nation-wide Austrian study","volume":"27","author":"Bsteh","year":"2021","journal-title":"Mult Scler"},{"key":"2023051801202580000_93.9.960.40","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103458","article-title":"Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England","volume":"57","author":"Garjani","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2023051801202580000_93.9.960.41","doi-asserted-by":"crossref","unstructured":"Bertoletti A , Tan AT , Le Bert N . The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. Oxf Open Immunol 2021;2:iqab006.doi:10.1093\/oxfimm\/iqab006","DOI":"10.1093\/oxfimm\/iqab006"},{"key":"2023051801202580000_93.9.960.42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140965"},{"key":"2023051801202580000_93.9.960.43","doi-asserted-by":"crossref","DOI":"10.1126\/science.abj9853","article-title":"Low-Dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells","volume":"374","author":"Mateus","year":"2021","journal-title":"Science"},{"key":"2023051801202580000_93.9.960.44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078532","article-title":"Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFN\u03b2-therapy","volume":"8","author":"Mehling","year":"2013","journal-title":"PLoS One"},{"key":"2023051801202580000_93.9.960.45","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1212\/NXI.0000000000000409","article-title":"Immune response to vaccines is maintained in patients treated with dimethyl fumarate","volume":"5","author":"von Hehn","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2023051801202580000_93.9.960.46","doi-asserted-by":"publisher","DOI":"10.1179\/1743132812Y.0000000059"},{"key":"2023051801202580000_93.9.960.47","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur J Neurol"},{"key":"2023051801202580000_93.9.960.48","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31829e6fbf"},{"key":"2023051801202580000_93.9.960.49","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211012835"},{"key":"2023051801202580000_93.9.960.50","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1007\/s10072-021-05397-7","article-title":"Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab","volume":"42","author":"Gallo","year":"2021","journal-title":"Neurol Sci"},{"key":"2023051801202580000_93.9.960.51","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jamaneurol.2021.5109","article-title":"Immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 vaccination","volume":"79","author":"K\u00f6nig","year":"2022","journal-title":"JAMA Neurol"},{"key":"2023051801202580000_93.9.960.52","doi-asserted-by":"crossref","first-page":"e1092","DOI":"10.1212\/NXI.0000000000001092","article-title":"COVID-19 infection in Fingolimod- or Siponimod-Treated patients","volume":"9","author":"Sullivan","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2023051801202580000_93.9.960.53","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(00)02126-6"},{"key":"2023051801202580000_93.9.960.54","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxq047"},{"key":"2023051801202580000_93.9.960.55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034830"},{"key":"2023051801202580000_93.9.960.56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.11.5761"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2022-329395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T04:22:43Z","timestamp":1684383763000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2022-329395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,8,12]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/jnnp-2022-329395"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2022-329395","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.02.06.22270550","asserted-by":"object"}]},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]}}}